Francesco Marabita

Francesco Marabita

Auto-generated profile, based on publicly available information

Francesco Marabita

Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2012 in Bioinformatics
Verified
Journal Article
Open access
PDF file
Andrew E. TeschendorffAndrew E. Teschendorff
Andrew E. Teschendorff
FMFrancesco Marabita
Francesco Marabita
MLMatthias Lechner
Matthias Lechner
TBThomas E Bartlett
Thomas E Bartlett
JTJesper Tegner
Jesper Tegner
SBStephan Beck
Stephan Beck
Motivation: The Illumina Infinium 450 k DNA Methylation Beadchip is a prime candidate technology for Epigenome-Wide Association Studies (EWAS). However, a difficulty associated with these beadarrays is that probes come in two different designs, characterized by widely different DNA methylation distributions and dynamic range, which may bias downstream analyses. A key statistical issue is therefore how best to adjust for the two different probe designs. Results: Here we propose a novel model-based intra-array normalization strategy for 450 k data, called BMIQ (Beta MIxture Quantile dilation), to adjust the beta-values of type2 design probes into a statistical distribution characteristic of type1 probes. The strategy involves application of a three-state beta-mixture model to assign probes to methylation states, subsequent transformation of probabilities into quantiles and finally a methylation-dependent dilation transformation to preserve the monotonicity and continuity of the data. We validate our method on cell-line data, fresh frozen and paraffin-embedded tumour tissue samples and demonstrate that BMIQ compares favourably with two competing methods. Specifically, we show that BMIQ improves the robustness of the normalization procedure, reduces the technical variation and bias of type2 probe values and successfully eliminates the type1 enrichment bias caused by the lower dynamic range of type2 probes. BMIQ will be useful as a preprocessing step for any study using the Illumina Infinium 450 k platform. Availability: BMIQ is freely available from http://code.google.com/p/bmiq/. Contact:a.teschendorff@ucl.ac.uk Supplementary information: Supplementary data are available at Bioinformatics online

3 August 2015 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
FMFrancesco Marabita
Francesco Marabita
Paola de CandiaPaola de Candia
Paola de Candia
ATAnna Torri
Anna Torri
JTJesper Tegnér
Jesper Tegnér
SASergio Abrignani
Sergio Abrignani
Riccardo Lorenzo RossiRiccardo Lorenzo Rossi
Riccardo Lorenzo Rossi
The high-throughput analysis of microRNAs (miRNAs) circulating within the blood of healthy and diseased individuals is an active area of biomarker research. Whereas quantitative real-time reverse transcription polymerase chain reaction (qPCR)-based methods are widely used, it is yet unresolved how the data should be normalized. Here, we show that a combination of different algorithms results in the identification of candidate reference miRNAs that can be exploited as normalizers, in both discovery and validation phases. Using the methodology considered here, we identify normalizers that are able to reduce nonbiological variation in the data and we present several case studies, to illustrate the relevance in the context of physiological or pathological scenarios. In conclusion, the discovery of stable reference miRNAs from high-throughput studies allows appropriate normalization of focused qPCR assays.

2 December 2014 in Epigenetics
Verified
Journal Article
Open access
MLMaléne E Lindholm
Maléne E Lindholm
FMFrancesco Marabita
Francesco Marabita
DGDavid Gomez-Cabrero
David Gomez-Cabrero
HRHelene Rundqvist
Helene Rundqvist
TETomas J Ekström
Tomas J Ekström
CSCarl Johan Sundberg
Carl Johan Sundberg
Regular endurance exercise training induces beneficial functional and health effects in human skeletal muscle. The putative contribution to the training response of the epigenome as a mediator between genes and environment has not been clarified. Here we investigated the contribution of DNA methylation and associated transcriptomic changes in a well-controlled human intervention study. Training effects were mirrored by significant alterations in DNA methylation and gene expression in regions with a homogeneous muscle energetics and remodeling ontology. Moreover, a signature of DNA methylation and gene expression separated the samples based on training and gender. Differential DNA methylation was predominantly observed in enhancers, gene bodies and intergenic regions and less in CpG islands or promoters. We identified transcriptional regulator binding motifs of MRF, MEF2 and ETS proteins in the proximity of the changing sites. A transcriptional network analysis revealed modules harboring distinct ontologies and, interestingly, the overall direction of the changes of methylation within each module was inversely correlated to expression changes. In conclusion, we show that highly consistent and associated modifications in methylation and expression, concordant with observed health-enhancing phenotypic adaptations, are induced by a physiological stimulus.

26 June 2011 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
Riccardo Lorenzo RossiRiccardo Lorenzo Rossi
Riccardo Lorenzo Rossi
GRGrazisa Rossetti
Grazisa Rossetti
LWLynn Wenandy
Lynn Wenandy
SCSerena Curti
Serena Curti
ARAnna Ripamonti
Anna Ripamonti
MPMassimiliano Pagani
Massimiliano Pagani

19 June 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
LKLara Kular
Lara Kular
YLYun Liu
Yun Liu
SRSabrina Ruhrmann
Sabrina Ruhrmann
GZGalina Zheleznyakova
Galina Zheleznyakova
FMFrancesco Marabita
Francesco Marabita
MJMaja Jagodic
Maja Jagodic
The human leukocyte antigen (HLA) haplotype DRB1*15:01 is the major risk factor for multiple sclerosis (MS). Here, we find that DRB1*15:01 is hypomethylated and predominantly expressed in monocytes among carriers of DRB1*15:01. A differentially methylated region (DMR) encompassing HLA-DRB1 exon 2 is particularly affected and displays methylation-sensitive regulatory properties in vitro. Causal inference and Mendelian randomization provide evidence that HLA variants mediate risk for MS via changes in the HLA-DRB1 DMR that modify HLA-DRB1 expression. Meta-analysis of 14,259 cases and 171,347 controls confirms that these variants confer risk from DRB1*15:01 and also identifies a protective variant (rs9267649, p < 3.32 × 10−8, odds ratio = 0.86) after conditioning for all MS-associated variants in the region. rs9267649 is associated with increased DNA methylation at the HLA-DRB1 DMR and reduced expression of HLA-DRB1, suggesting a modulation of the DRB1*15:01 effect. Our integrative approach provides insights into the molecular mechanisms of MS susceptibility and suggests putative therapeutic strategies targeting a methylation-mediated regulation of the major risk gene.

1 March 2013 in Epigenetics
Verified
Journal Article
Open access
FMFrancesco Marabita
Francesco Marabita
MAMalin Almgren
Malin Almgren
MLMaléne E. Lindholm
Maléne E. Lindholm
SRSabrina Ruhrmann
Sabrina Ruhrmann
FFFredrik Fagerström-Billai
Fredrik Fagerström-Billai
DGDavid Gomez-Cabrero
David Gomez-Cabrero
The proper identification of differentially methylated CpGs is central in most epigenetic studies. The Illumina HumanMethylation450 BeadChip is widely used to quantify DNA methylation; nevertheless...